Neurology News

High efficacy and acceptability were demonstrated in both on-label and off-label medications for fibromyalgia, reinforcing the value of symptom-based treatment plans, according to a study published in JAMA Network Open.

NEW ORLEANS – A number of new treatments are on the horizon for PTSD, making the future bright for patients with this condition, Charles B. Nemeroff, MD, PhD, said at the American Psychiatric Association annual meeting.

Compared with infants born before the COVID-19 pandemic, those born during the pandemic had decreased fetal brain development, which researchers found was linked to higher levels of distress in women giving birth during the pandemic.

Prenatal exposure to topiramate, valproate and select duotherapies was associated with increased risk for autism spectrum disorder and intellectual disability, according to a study published in JAMA Neurology.

VeriSIM Life announced it will partner with neuroscience firm Total Brain to develop new drugs for the treatment of a wide range of neurological disorders, the company announced through a press release.

HHS announced that Medicare Part B premiums paid in 2022 should be lowered in 2023 to account for an overestimate in costs related to inclusion of Aduhelm within the Medicare program for reimbursement.

Genentech announced that the FDA approved a label extension for Evrysdi to include infants younger than 2 months with spinal muscular atrophy.

Seizure- and epilepsy-related emergency department visits decreased during the COVID-19 pandemic compared with pre-pandemic levels, with the largest drop seen among young children, per a study in MMWR.

The FDA has granted priority review to Reata Pharmaceuticals Inc.’s new drug application for omaveloxolone to treat patients with Friedreich’s ataxia.

Long-term supplementation with spermidine improved neither memory function nor biomarkers compared with placebo in older adults with subjective cognitive decline, according to results of a clinical trial published in JAMA Network Open.